(Q43837625)

English

IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy

scientific article published on 3 July 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Hiroaki Motegi

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Yuuta Kamoshima

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Shunsuke Terasaka

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Hiroyuki Kobayashi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Shigeru Yamaguchi

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Mishie Tanino

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Junichi Murata

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Kiyohiro Houkin

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

3 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Brain Tumor Pathology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

67-72

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Evaluation of malignant glioma patients during the postirradiation period

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Pseudoprogression and pseudoresponse in the treatment of gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Mechanisms of radiation injury to the central nervous system: implications for neuroprotection

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Glioblastoma stem-like cells give rise to tumour endothelium.

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0109-X

21 January 2018

Identifiers

10.1007/S10014-012-0109-X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43837625&oldid=2206286085"